Author leans toward WELL Health because the stock has fallen sharply and expectations appear already low, implying potential recovery upside over the next 6 months. The bull case rests on continued revenue growth and management raising guidance, though the author flags heavy debt, aggressive acquisitions, and profits that look weaker than adjusted EBITDA as key risks.